Apexigen, Inc.

Apexigen, Inc. (CIK 0001814140) is a clinical-stage biopharmaceutical company focused on oncology antibody therapeutics that participated in the SPAC market during the 2020–2021 cycle. The company filed an 8-K current report with the Securities and Exchange Commission on February 2, 2021, reflecting a material corporate event during the peak of blank-check company activity. Apexigen's path to the public markets was facilitated through a de-SPAC transaction with Brookline Capital Acquisition Corp, a life sciences-focused blank-check vehicle sponsored by Brookline Capital Markets that completed its IPO in 2020. The combined entity targeted next-generation antibody-based cancer immunotherapy as its core development mandate. Sign up for SpacDesk to access complete filing histories, sponsor profiles, and deal analytics across the entire SPAC universe.